Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. ...

Dividend stocks trading at discounted prices can make for great investments if you're willing to be patient. That's because, assuming their payouts are sustainable, you can lock in a higher yield than normal. You may also benefit from a rising share price in the future should their valuations recover.Three dividend stocks that are cheap buys today, offer high yields, and could be good long-term plays include AstraZeneca (AZN -0.55%), ExxonMobil (XOM 0.39%), and Toronto-Dominion Bank (TD 0.81%). Here's a clo ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiov ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsuit.  Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZeneca class action lawsuit charges AstraZeneca as well as certain of Astra ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=121997&from=4 CLASS PERIOD: February 23, 2022 to ...

Lawsuit Overview - The lawsuit alleges that AstraZeneca failed to disclose its involvement in insurance fraud in China, leading to heightened legal exposure and the detention of its China President by Chinese authorities [3] - The company is accused of understating its legal risks, which could materially harm its business activities in China [3] - Defendants' positive statements about the company's business, operations, and prospects are claimed to be materially misleading and/or lacking a reasonable basis [3] Legal Action Details - Investors who suffered losses in AstraZeneca PLC (AZN) have the opportunity to lead the securities fraud class action lawsuit [1] - The deadline for lead plaintiff participation is February 21, 2025 [2] - Investors can contact the Law Offices of Howard G. Smith to discuss their legal rights and participate in the lawsuit [2][4] Class Action Participation - Investors do not need to take any action to be a member of the class action; they may retain counsel of their choice or remain an absent member [5] - The press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules [5]

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

Growth Stocks Overview - Many growth stocks are trading at high valuations, suggesting limited near-term upside potential [1] - Long-term investors may consider rebalancing portfolios by selling recent high performers and buying cheaper growth stocks for better long-term gains [1] AstraZeneca (AZN) - Leading healthcare company investing in next-generation oncology therapies that are more targeted than traditional chemotherapy or radiation [3] - Acquired Fusion Pharmaceuticals, a clinical-stage company developing radioconjugates for precise cancer treatment [4] - Revenue target of $80 billion by 2030, up from $51 billion over the past four quarters [4] - Stock fell 3% last year, trading at a forward P/E of 14, significantly lower than the healthcare sector average of 20 [5] - Potential to be one of the best healthcare stocks over the next five-plus years if growth targets are met [5] Uber Technologies (UBER) - Ride-hailing company with shares down 2% last year due to overblown concerns about competition from Alphabet's Waymo [6] - Remains a dominant and practical option for consumers with strong growth and surging profits [7] - Revenue increased 17% to over $32 billion in the first nine months of 2024, with operating profit jumping from $458 million to over $2 billion year-over-year [7] - Attractive valuation with a forward P/E of 25 and a PEG ratio of around 0.70, supported by improving fundamentals and strong growth prospects [8] Zoom Communications (ZM) - Videoconferencing company still growing despite being perceived as a pandemic play [9] - Zoom's ease of use and flexibility make it a preferred choice over Microsoft Teams, even for organizations with Microsoft 365 subscriptions [10] - Revenue grew 3% year-over-year to $3.5 billion in the nine months ending Oct 31, with a low monthly churn rate of 2.7% [11] - Expanding product offerings with AI features and solutions like Zoom Mail, supporting long-term growth [11] - Stock trades at a modest forward P/E of 15, making it an attractive growth stock to buy and hold [12]